ClinicalTrials.gg
Status unknownNCT03046342GEUpdated Mar 22, 2024

Gastroenteritis in Pediatric Population of Qatar

An observational study in Gastroenteritis, sponsored by Hamad Medical Corporation. Status unknown at 1 site in Qatar. Open to participants aged 3 Months to 14 Years. Per ClinicalTrials.gov, last updated 2024-03-22.

Sponsored by Hamad Medical Corporation · Observational

How we know

The sponsor has not verified this record recently (last verified Feb 2023), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
3,000
Ages
3 Months to 14 Years
Sex
All
01

Study summary

Comparison of clinical and laboratory diagnosis for cause of Gastroenteritis(GE) depending on the clinical manifestation.Identifying the sources of viral, bacterial and parasitic GE in Pediatric population of Qatar

Read the detailed description

Processing of stool samples by molecular method (PCR) for children with GE including complete data collection. Patients are followed up for 14 days

02

Conditions studied

  • Gastroenteritis

Browse trials for

Keywords

  • Gastroenteritis, Polymerase chain reaction
03

In context

Gastroenteritis

237 studies on the registry are indexed under Gastroenteritis; 16 are open to participants now.

This study's planned enrollment of 3,000 is above the median of 606 across 62 observational studies indexed under Gastroenteritis.

Browse Gastroenteritis studies →

Lead sponsor

Hamad Medical Corporation is the lead sponsor of 139 studies on the registry; 27 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Months to 14 Years
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

All acute gastroenteritis patients between 3 months to 14 years presenting to PEC centers with acute diarrhea+/- vomiting with or without fever

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • All acute gastroenteritis patients between 3 months to 14 years presenting to PEC centers with acute diarrhea+/- vomiting with or without fever

Exclusion criteria

Exclusion Criteria:

  1. Cases of vomiting +/- fever only without diarrhea
  2. Suspicion of surgical abdomen
  3. Bile stained vomitus
  4. Mal-absorption diseases as cystic fibrosis, celiac disease or increased secretion as disaccharides deficiency
  5. Cases of Inflammatory bowel disease
  6. Antibiotic associated diarrhea
  7. Patients with immune deficiency
  8. Patients with chronic diarrhea (>2 weeks of diarrhea)
  9. Patients receiving long term medication for any disease
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
3,000 participants (estimated)
Patient registry
No

Interventions

  • Diagnostic testMolecular method (PCR)

    Stool samples are being processed through molecular method (PCR) for children with GE. Epidemiology of acute Gastroenteritis in the pediatric population in Qatar

06

What researchers measure

Primary outcomes

  1. sources of viral, bacterial and parasitic GE in the country

    Prevalence of viral, bacterial and parasitic GE in children \< 14 years of age in Qatar will be identified by molecular method sample processing

    Time frame: 4 years

Secondary outcomes

  1. seasonal variation of GE in qatar determination

    seasonal variation of GE in qatar being determined by number of cases reported during each season

    Time frame: 4 years

  2. comparing the prevalence of viral GE in vaccinated children in Qatar (against rotavirus) and the other countries which implemented rotavirus vaccine

    comparing the prevalence of viral GE in vaccinated children in Qatar (against rotavirus) and the other countries which implemented rotavirus vaccine by detection of source of GE in vaccinated children by molecular method.

    Time frame: 4 years

07

Study locations

1 of 1 sites recruiting
  • Hamad medical corporation
    Doha, 3050, Qatar
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2015 (actual). Primary completion is estimated for Sep 2024, 114 months after the start.

Of 17 observational studies under Gastroenteritis, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 161. This study's planned 114 months is above that.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 31, 2017
First posted
Feb 8, 2017
StartActual
Mar 10, 2015
Primary completionEst.
Sep 10, 2024
CompletionEst.
Dec 10, 2024
Last update
Mar 22, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 22, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03046342
Responsible party
Sponsor
First posted
Feb 8, 2017
Start date
Mar 10, 2015
Primary completion
Sep 10, 2024 (estimated)
Completion
Dec 10, 2024 (estimated)
Last update
Mar 22, 2024

Study contacts

Dr.Khalid Alansari
Contact
kalansari1@hamad.qa
+974 55336166

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Feb 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion